Evidence map›Paper›PMID 39943794›Full record

ArticleDrug testing and analysis2025

Identification and Investigation of the Intrinsic Receptor Activation Potential and Metabolization of the New Oxo-Pyridyl Synthetic Cannabinoid Receptor Agonist CH-FUBBMPDORA.

Marie H Deventer, Maria Carmela Emanuele, Brianna N Stang, Katleen Van Uytfanghe, Jessica Masson, Xavier Bouvot, Catherine Lamoureux, Alessandro Proposito, Fabiano Reniero, Margaret V Holland and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug testing and analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marie H DeventerLaboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Maria Carmela EmanueleUfficio Laboratori, Agenzia delle Dogane e dei Monopoli, Rome, Italy.
Brianna N StangCenter for Forensic Science Research and Education, Fredric Rieders Family Foundation, Horsham, Pennsylvania, USA.
Katleen Van UytfangheLaboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
Jessica MassonLaboratoire de Paris, Service Commun de Laboratoire DGCCRF-DGCCI (SCL), Massy, France.
Xavier BouvotLaboratoire de Paris, Service Commun de Laboratoire DGCCRF-DGCCI (SCL), Massy, France.
Catherine LamoureuxLaboratoire de Paris, Service Commun de Laboratoire DGCCRF-DGCCI (SCL), Massy, France.
Alessandro PropositoUfficio Laboratori, Agenzia delle Dogane e dei Monopoli, Rome, Italy.
Fabiano RenieroJoint Research Centre (JRC), European Commission, Ispra, Italy.
Margaret V HollandJoint Research Centre (JRC), European Commission, Ispra, Italy.
Alex J KrotulskiCenter for Forensic Science Research and Education, Fredric Rieders Family Foundation, Horsham, Pennsylvania, USA.
Luisa ManninaFood Chemistry Lab, Department of Chemistry and Technology of Drugs, Sapienza University of Rome, Rome, Italy.
Christophe P StoveLaboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.ORCID https://orcid.org/0000-0001-7126-348X
Claude GuillouJoint Research Centre (JRC), European Commission, Ispra, Italy.ORCID https://orcid.org/0000-0002-6210-3457

Funding

European Commission Directorate General for Taxation and Customs Unions (DG TAXUD) JRC-Nr 36204-2021-DG TAXUD-Nr TAXUD/2021/DE/319European Commission Directorate General for Taxation and Customs Unions (DG TAXUD) JRC-Nr 36204-2021 -DG TAXUD-Nr TAXUD/2021/DE/319Fonds Wetenschappelijk Onderzoek 1S54521NNational Institute of Justice, Office of Justice Programs, U.S. Department of Justice 15PNIJ-22-GG-04434-MUMU
6 · The paper itself

Abstract

CH-FUBBMPDORA (CHO-4'Me-5'Br-FUBOXPYRA), a recent addition to the recreational drug market, bypasses the Chinese generic ban (2021) on synthetic cannabinoid receptor agonists (SCRAs) due to its new 5-bromo-4-methylpyridin-2(1H)-one core. Its pharmacological properties are currently undefined, and it is yet to be found in biological samples. However, it is unclear whether this is due to low prevalence or hampered detection. The aim of this study was twofold. First, we used a powder seized by customs as a case study to evaluate the utility of low-field nuclear magnetic resonance (LF-NMR) to unequivocally identify CH-FUBBMPDORA. This demonstrated the potential of this technique, which is increasingly used by customs and forensic laboratories for substance identification. High-field nuclear magnetic resonance (HF-NMR), Fourier transform infrared spectrometry (FTIR), gas chromatography-mass spectrometry (GC-MS), liquid chromatography coupled to time-of-flight mass spectrometry (LC-QTOF-MS), and Raman spectroscopy were used as complementary techniques for identification and characterization. Second, we investigated the potential to activate CB

Indexed as

Cannabinoid Receptor AgonistsIllicit DrugsPyridinesReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2CannabinoidsChromatography, LiquidGas Chromatography-Mass SpectrometryHumansMagnetic Resonance SpectroscopySpectroscopy, Fourier Transform InfraredCannabinoid Receptor AgonistsCannabinoidsIllicit DrugsPyridinesReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2

Identifiers

PMID39943794
PMCPMC12401638

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.